Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
23/09/2026 11:57
BRIEF-Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension Sept 23 (Reuters) - ANI Pharmaceuticals, Inc. ANIP.O:
ANI PHARMACEUTICALS ANNOUNCES THE FDA APPROVAL OF EVEROLIMUS TABLETS FOR ORAL SUSPENSION
Source text: ID:nGNX41vknK
Further company coverage: ANIP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary